Cardiac Phenotype and Clinical Outcomes in Randall Disease versus Light-Chain Amyloidosis

Amyloid · Published 2025-11-21 · DOI 10.1080/13506129.2025.2589888

Authors being retrieved — see the publisher record. https://doi.org/10.1080/13506129.2025.2589888

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2025

Related articles

• ALyzer3D.AI: a more generalizable deep learning predictor of light chain amyloidogenicity powered by structural and evolutionary Artificial Intelligence · Amyloid · 2025 · Same journal
• Long-term efficacy and safety of vutrisiran in hereditary transthyretin amyloidosis with polyneuropathy: final analysis of the HELIOS-A randomized treatment extension · Amyloid · 2026 · Same journal
• Limited diagnostic utility of systematic Congo red staining in bone marrow biopsies · Amyloid · 2025 · Same journal
• Clinical profile and outcome of AA amyloidosis associated kidney disease in India · Amyloid · 2025 · Same journal
• Medin and transthyretin: a new amyloid double act in the aortic wall and valves · Amyloid · 2025 · Same journal
• Clinical and radiological stabilization following vutrisiran treatment in transthyretin leptomeningeal amyloidosis: a case report · Amyloid · 2025 · Same journal
• Clinical significance of gastric food residue in gastrointestinal hereditary transthyretin amyloidosis · Amyloid · 2026 · Same journal
• Proline-rich, polybasic peptides are a structurally distinct class of amyloid-reactive peptides · Amyloid · 2026 · Same journal
• Detection yield of surrogate tissue biopsies across amyloidosis classes: a large-scale analysis of 4,027 patients · Amyloid · 2025 · Same journal
• Diagnostic utility of deep excisional skin biopsy including abdominal fat for transthyretin cardiac amyloidosis · Amyloid · 2026 · Same journal